Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol Myers Squibb Continues Its Legacy with 93-Year Dividend Streak

December 14, 2024
Bristol Myers Squibb (BMY), a leading pharmaceutical company, has extended its impressive 93-year dividend streak with a 16th consecutive annual increase. This announcement comes as a reflection of the company's commitment to providing consistent returns to its shareholders.

Bristol Myers Squibb has been a top socially responsible dividend stock, with a yield of 4%. The company has prioritized sustainable and responsible business practices, making it an attractive choice for investors seeking both financial growth and social impact.

In addition to its impressive dividend history, Bristol Myers Squibb has been making waves in the healthcare industry. The company's latest appointment of Tim Power as the Head of Investor Relations at Biogen showcases its determination to strengthen investor relations and communicate effectively with stakeholders.

With a solid track record and a focus on long-term growth, Bristol Myers Squibb is positioned as a great value stock. Investors looking to capitalize on the company's success should consider consulting professionals from Stocks Prognosis for an expert forecast of its future stock movement.

As Bristol Myers Squibb continues to make a positive impact in the pharmaceutical industry, its dedication to innovation, shareholder value, and responsible business practices makes it an attractive choice for long-term investors.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

I've been following Bristol Myers Squibb closely and I'm confident that their dedication to shareholder value and strong dividend history will continue to benefit investors
— from GraceStewart at 12-17-2024 16:59
While Bristol Myers Squibb's dividend streak is impressive, I'm concerned about the potential risks in the healthcare industry. There's always the possibility of regulatory changes and market disruptions
— from MoneyMabel at 12-17-2024 02:01
I'm impressed by Bristol Myers Squibb's long dividend streak and their focus on social responsibility. It's definitely a company I want to keep an eye on
— from IsaacPerry at 12-16-2024 20:53
Bristol Myers Squibb's track record and focus on long-term growth make it a valuable stock to consider. I'm excited to see what the future holds for this pharmaceutical company
— from RobertWhite at 12-16-2024 15:09
I'm not convinced that Bristol Myers Squibb's dividend streak is sustainable in the long run. Pharmaceutical companies face a lot of challenges and it's hard to predict how their future performance will be
— from EllaFlores at 12-16-2024 14:47
Great news! I've been a shareholder of Bristol Myers Squibb for years and it's always reassuring to see their commitment to consistent returns
— from MoneyJoe at 12-16-2024 12:52
I'm not sure if the 16th consecutive annual increase in dividends is enough to outweigh the risks associated with investing in pharmaceutical companies. It's a highly competitive and volatile industry
— from SavingsSarah at 12-16-2024 07:24
I've heard a lot of positive things about Bristol Myers Squibb lately. Their dedication to sustainable business practices and strong dividend history make them an attractive investment option
— from TraderTara at 12-15-2024 20:07
Bristol Myers Squibb's recent appointment of Tim Power as the Head of Investor Relations shows their commitment to effective communication and strengthening relationships with stakeholders
— from WealthyWill at 12-15-2024 17:06
I'm glad to see Bristol Myers Squibb's commitment to innovation and responsible business practices. It's great to see a company in the healthcare industry taking social impact seriously
— from VictoriaGreen at 12-15-2024 02:46
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....

BMYApril 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave  ~2 min.

BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....



Related news

ABTDecember 1, 2024Abbott Laboratories: A Leading Pharmaceutical Company in the Hands of Institutional Shareholders  ~1 min.

Abbott Laboratories, a renowned pharmaceutical company traded on the NYSE under the ticker symbol ABT, is currently experiencing significant control from institutional shareholders....

AZNFebruary 2, 2025Shareholders of AstraZeneca PLC Should Contact Levi Korsinsky Before February 21 2025 to Discuss Your Rights  ~2 min.

It has come to light that shareholders of AstraZeneca PLC (AZN) are urged to contact Levi Korsinsky, a renowned law firm specializing in securities litigation, before February 21, 2025, to discuss their rights. AstraZeneca PLC, a global pharmaceutical company, has been facing potential legal implications due to recent developments in the industry. Levi Korsinsky is currently investigating possible...

BMYDecember 31, 2024Bristol-Myers Squibb Strengthens Investor Confidence with Increased Dividend Payout  ~1 min.

Bristol-Myers Squibb, a renowned pharmaceutical company listed on the NYSE as BMY, has announced a significant increase in its dividend payout compared to the previous year....

PFENovember 16, 2024Investors Show Interest in Pfizer Inc. PFE as Company Announces Strategic Vision at Healthcare Conference  ~1 min.

Pfizer Inc. (NYSE:PFE) has attracted the attention of investors as the pharmaceutical giant reveals its strategic vision at the Jefferies London Healthcare Conference....

UNHJanuary 1, 2025UnitedHealth Group Incorporated: A Promising Investment Opportunity  ~2 min.

UnitedHealth Group Incorporated (UNH) has been making significant strides in the healthcare industry, positioning itself as a leader in providing innovative healthcare solutions....